Annotation Detail
Information
- Associated Genes
- ALK
- Associated Variants
- ALK ALK FUSIONS ALK ALK FUSIONS
- Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- In a phase 2 trial, patients with NSCLC with ALK fusion received lorlatinib. In treatment-naive patients, ORR was 90.0% In patients with at least one previous ALK tyrosine kinase inhibitor, ORR were achieved in 47.0%.In patients who had only received crizotinib ORR was achieved in 69.5%.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/7286
- Gene URL
- https://civic.genome.wustl.edu/links/genes/1
- Variant URL
- https://civic.genome.wustl.edu/links/variants/499
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Lorlatinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 30413378
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Lorlatinib | Sensitivity | true |